The rodent non-genotoxic hepatocarcinogen Nafenopin and EGF alter the mitosis/apoptosis balance promoting hepatoma cell clonal growth.
The responses of a series of rat hepatoma cell lines (FaO, HTC, RH1) to the rodent non-genotoxic hepatocarcinogen and per-oxisome proliferator (PP) Nafenopin were studied to determine if this PP acts with EGF, a naturally occurring liver growth regulator, to perturb the balance between mitosis and apoptosis. EGF enhanced the growth of FaO cells (well differentiated) and HTC cells (intermediate differentiation) but not of the poorly differentiated RH1 cell line. Nafenopin also increased FaO cell growth but, surprisingly, retarded the growth of both HTC and RH1 cells. Since population expansion kinetics result from mitosis and death, replicative DNA synthesis (RDS) and apoptotic cell death were measured in HTC cells. As expected, EGF elevated RDS and suppressed cell death. However, Nafenopin depressed HTC net population expansion via a suppression of cell death coupled to a more marked inhibition of RDS. This apparent paradox was investigated using soft agar cloning. This revealed sub-populations with differing growth kinetics suggesting selective clonal expansion via an alteration in the balance between mitosis and apoptotic cell death. At later stages, cells are refractory to EGF and Nafenopin, suggesting that genetic changes may have superseded such factor-dependence.